We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Register Free
Advertise with Us
Latest Issue
Latest Issue

Download Mobile App




In Other News

Image Genetic testing confirms whether insulin excess arises from the entire pancreas (diffuse disease) or from a localized pancreatic region (focal disease) (image credit: 123RF)

Genomic Testing Program Improves Diagnosis of Congenital Hyperinsulinism

Congenital hyperinsulinism causes recurrent hypoglycemia in infancy and can lead to brain injury, with neurologic damage affecting about 40% of children with the condition. Read more
11 May 2026 | Molecular Diagnostics
Image: Using a method that identifies the origin of DNA fragments, researchers found neutrophil levels closely reflected gut inflammation severity in pediatric and adult patients (photo credit: Shutterstock)

Stool DNA Analysis Tracks Disease Activity in IBD

Inflammatory bowel disease (IBD) affects an estimated 6–8 million people worldwide and is commonly monitored through colonoscopy and stool testing. Read more
11 May 2026 | Molecular Diagnostics
Image: Researchers identified blood-based genomic signatures characteristic of inflammatory breast cancer (photo courtesy of Shutterstock)

Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring

Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Read more
08 May 2026 | Molecular Diagnostics
Image: Small cell lung cancer is an aggressive malignancy that often responds to initial chemotherapy but commonly relapses, creating an urgent need for reliable resistance biomarkers (image credit: Shutterstock)

Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer

Small cell lung cancer (SCLC) is an aggressive malignancy that often responds to initial chemotherapy but commonly relapses, creating an urgent need for reliable resistance biomarkers. Read more
08 May 2026 | BioResearch
Image:The transaction is expected to close in the second half of 2026, with Roche paying USD 750 million upfront and up to USD 300 million in additional milestone payments

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio

Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry. Read more
08 May 2026 | Industry
Image: The findings could enable noninvasive liquid biopsy profiling of the complex tumor microenvironment, helping guide precision oncology decisions across cancers and therapies (Photo credit: Shutterstock)

Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response

Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins. Read more
08 May 2026 | Molecular Diagnostics
Image: ArteraAI Breast analyzes digitized histopathology images alongside patient clinical variables to produce an AI-derived risk score that provides prognostic insight into the likelihood of distant metastasis (Image credit: Adobe Stock)

FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification

Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment and undertreatment remain clinical concerns. Read more
07 May 2026 | Pathology
Image: Overall workflow of the study. Targeted genes are ITGAM, PECAM1, CCL5, STAT1, STAT2, and CD44. (Dipanwita Nath et al, Cancer Medicine (2026). DOI: 10.1002/cam4.71775)

Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with late diagnosis, limited treatment options, and frequent relapse. Read more
07 May 2026 | BioResearch
Image: Tissue sample spatial analysis (on left) and standard H&E image (on right) (Photo courtesy of QIMR Berghofer Medical Research Institute)

New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides

Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease. Read more
07 May 2026 | Pathology
Image: The workflow seamlessly integrates the KingFisher Flex platform with the BioCode MDx-3000 system to expand panel utility and increase respiratory testing throughput (Photo courtesy of Thermo Fisher Scientific)

Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing

Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Read more
07 May 2026 | Molecular Diagnostics
Image: Blood RNA markers potential for detecting HIV and tuberculosis complications and tracking treatment response in inflammatory bowel disease (Photo courtesy of Shutterstock)

Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response

Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Read more
07 May 2026 | Molecular Diagnostics
Image: The findings provide the first evidence that pre-treatment epigenetic signals in cfDNA can distinguish semaglutide responders from non-responders, with important implications for the future of precision medicine in GLP-1 therapy (Photo credit: Adobe Stock)

Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects

Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale. Read more
07 May 2026 | Molecular Diagnostics
Image: Schematic diagram of the microfluidic chip platform (D.Adnan, N. R.deBarros, L. S.Santovito, et al., Advanced Science (2026). DOI: 10.1002/advs.202508934)

Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response

Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Read more
07 May 2026 | Technology
Image: These findings suggest tumor transcriptomic errors may provide a predictive framework for personalizing treatment in metastatic kidney cancer (photo courtesy of Shutterstock)

Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer

Selecting effective therapy for metastatic renal cell carcinoma (mRCC) is challenging because reliable predictive biomarkers are scarce. Read more
07 May 2026 | BioResearch

Channels

Clinical Chemistry

view channel
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
Blood Test Detects Testicular Cancer Missed by Standard Markers
Routine Blood Tests Identify Biomarkers Linked to PTSD
Image: The dSAA method partitions a patient’s cerebrospinal fluid into nanoliter-scale compartments and digitally counts the number of TDP-43 protein “seeds” present under a microscope (image credit: Shutterstock)

Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype

Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more

Molecular Diagnostics

view channel
Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
Image: The findings support tumor genomic testing in pituitary carcinomas and aggressive pituitary adenomas, to guide consideration of immunotherapy as a potential first-line option (photo courtesy of Adobe Stock)

Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors

Aggressive pituitary tumors are rare and difficult to manage, and many cases respond poorly to surgery, radiation, and temozolomide. Recurrence and resistance create an urgent need for treatment strategies... Read more

Hematology

view channel
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Image: The indices are presented through intuitive software on the Aquila, Aquarius 3, and Abacus 5 analyzers (photo courtesy of Diatron)

Advanced CBC-Derived Indices Integrated into Hematology Platforms

Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more

Immunology

view channel
T-Cell Senescence Profiling May Predict CAR T Responses
Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Image: Schematic of Mpox diagnostic methods.(A) Artificial intelligence (AI)-enhanced image classification can be leveraged to classify lesions concerning for Mpox, particularly in low resource settings where specialists (i.e., infectious disease specialists or dermatologists) are not available. (B) Clinical specimens (including nasal swabs, lesion swabs, or serum samples) can be used for molecular or biochemical confirmation of Mpox infection. (C) Rapidly, field-deployable devices or assays can be developed using various strategies(Mpox) diagnostic methods (Yilgic D, Ergonul O, Tasoglu S. Mpox diagnosis at POC. Trends in Biotechnology. DOI: 0.1016/j.tibtech.2025.04.015)

Point-of-Care Tests Could Expand Access to Mpox Diagnosis

Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more

Microbiology

view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Image: Biosensor for tuberculosis detection (photo courtesy of UPV)

Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour

Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more

Pathology

view channel
New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Image: SPARK overview, data structure and study design (Trost, F., Zhang, B., Aring, I. et al. https://doi.org/10.1038/s41591-026-04357-y)

AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes

The digital transformation of pathology is expanding how cancers are evaluated in routine practice. Artificial intelligence (AI) is increasingly applied to routinely collected histological tissue sections,... Read more

Technology

view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Image: Abstract (Tamrin SH, Sanati Nezhad A, Sen A. ACS Omega. 2025;10(50):61568–61579. doi:10.1021/acsomega.5c07331)

New Platform Captures Extracellular Vesicles for Early Cancer Detection

Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more

Industry

view channel
CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
Thermo Fisher Scientific to Sell Microbiology Business to Astorg
Collaboration Expands Access to Rapid Metagenomic Diagnostics for Complex Infect...
Image: The approval enables clinical laboratories to use a validated, blood-based method to determine eligibility for the targeted therapy (photo courtesy of Guardant Health)

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy

Endocrine therapy resistance remains a significant challenge in estrogen receptor–positive, human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer, where tumor evolution can limit... Read more

LabMedica

About Us
Advertising Info
Subscription
Client Login
Privacy Policy
Terms of Service
Cookie Policy
Journal Info
Contact Us

Channels

Clinical Chem.
Molecular Diagnostics
Hematology
Immunology
Microbiology
Pathology
Technology
BioResearch
Industry
Events
Focus
Webinars

Features

Events Product Showcase LinkXpress Whitepapers archive Video Library

Partner Sites

LabMedica ExpoHospiMedica.com Globetech.net

Archive:

BioResearch
COVID-19

2026
WHX Labs Dubai 2025
Medica ADLM MEDLAB 2024
Medica ADLM

 

Medlab 2023
Medica AACC EUROMEDLAB Medlab 2022
MEDICA AACC ECCMID
Copyright © 2000-2026 Globetech Media. All rights reserved.
MOBILE | FULL SITE